Bypassing the Blood-Brain Barrier: A Dual-Axis Framework for Alzheimer's Disease Utilizing Glymphatic-Lymphatic Clearance and In Situ Chaperone Synthesis

Alzheimer's disease (AD) poses a dual proteotoxic challenge: extracellular amyloid-beta plaque accumulation and intracellular hyperphosphorylated tau aggregation. Conventional systemic therapies struggle to clear macromolecular waste from the brain parenchyma or to cross the blood-brain barrier (BBB) and intercept intracellular misfolding. This framework proposes active craniospinal tensioning (ACT), a single non-invasive maneuver combining dural pull-recoil with targeted suboccipital venous occlusion-rebound, hypothesized to produce two coupled therapeutic effects: macroscopic craniospinal waste clearance and localized intra-axial cytoprotection, the latter termed cerebral venous preconditioning (CVPC). Regarding the proposed macro-fluidic axis (glymphatic-lymphatic clearance), we propose that suboccipital venous occlusion transiently congests the dural sinuses and that the abrupt release of this occlusion produces a rapid antegrade venous outflow surge. Because glymphatic efflux travels through the perivenous space immediately adjacent to these vessels, we hypothesize that this hemodynamic rebound exerts a convective drag on the perivenous fluid compartment, accelerating clearance of amyloid-beta and tau complexes suspended there by the coupled dural pull-recoil mechanism. This accelerated perivenous efflux is proposed to feed the brain's established downstream clearance routes, namely, drainage into the dural venous sinuses via arachnoid granulations and into meningeal lymphatics via deep cervical lymph nodes, thereby bypassing the restriction imposed by the BBB on direct interstitial waste clearance. This fluid-dynamic mechanism is theoretical and has not yet been directly measured. Regarding the proposed micro-biochemical axis (CVPC, in situ chaperone synthesis), CVPC is conceptually modeled after ischemic preconditioning, with remote ischemic preconditioning (RIPC) as the most extensively studied form. Among RIPC's reported downstream effects, circulating heat shock protein (HSP) elevation is one well-characterized humoral mediator; however, these ~70 kDa chaperones are generally excluded from BBB crossing given the barrier's approximate small-molecule passive permeability limit of ~0.4 kDa, which constrains RIPC's central nervous system (CNS) effects largely to indirect humoral and neural signaling. We hypothesize that the same occlusion-rebound cycle instead acts locally: retrograde venous wall distension and transient mild hypoxia during occlusion at the craniospinal microvasculature, followed by shear stress during the rebound surge, may activate heat shock factor 1 (HSF-1), driving in situ synthesis of HSP 70 (HSP70) within endothelial cells, astrocytes, and neurons. We further propose that locally synthesized HSP70 could bind and stabilize early tau intermediates, limiting hyperphosphorylation and aggregation, a mechanism grounded in established HSP-tau chaperone biology but not yet demonstrated for this specific maneuver. If validated, ACT would offer a single, non-invasive strategy that combines macro-mechanical extracellular clearance with micro-biochemical intracellular cytoprotection, potentially altering the AD trajectory without the systemic liabilities associated with elevated circulating HSP levels and without dependence on BBB-crossing agents. These proposed mechanisms require preclinical and clinical validation before any therapeutic claims can be made.